CorMedix CEO granted 225,900 RSUs in Form 4

CorMedix Inc.’s Chief Executive Officer and director Joseph Todisco reported an equity award and related share transaction.

Rhea-AI Filing Summary

CorMedix Inc.’s Chief Executive Officer and director Joseph Todisco reported an equity award and related share transaction. On 01/23/2026, he received 225,900 restricted stock units, each representing one share of common stock, at a price of $0.00.

The restricted stock units vest 1/4 on the grant date and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant. On the same date, a second transaction labeled code F covered 27,306 shares at $7.27 per share, leaving Todisco with 697,593 common shares held directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Todisco Joseph

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	225,900	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	27,306	$7.27	$199K

Holdings After Transaction: Common Stock — 697,593 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units granted on 01/23/2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CorMedix Inc. (CRMD) CEO Joseph Todisco report?

Joseph Todisco reported receiving 225,900 restricted stock units on 01/23/2026. Each unit represents one share of CorMedix common stock, with a vesting schedule over four years, alongside a separate transaction involving 27,306 common shares at $7.27 per share.

How many CorMedix (CRMD) shares does CEO Joseph Todisco own after this Form 4?

After the reported transactions, Joseph Todisco directly owns 697,593 shares of CorMedix common stock. This figure reflects the grant of 225,900 restricted stock units and a separate transaction involving 27,306 shares on 01/23/2026, as disclosed in the Form 4 filing.

What is the vesting schedule for Joseph Todisco’s 225,900 CorMedix (CRMD) RSUs?

The 225,900 restricted stock units vest 1/4 on the grant date, then 1/4 on each of the first, second, and third anniversaries. Continued employment is required for the later vesting tranches, tying Todisco’s equity compensation to ongoing service with CorMedix.

What were the transaction codes used in Joseph Todisco’s CorMedix (CRMD) Form 4?

The Form 4 shows transaction code A for the award of 225,900 restricted stock units at $0.00 and code F for a transaction of 27,306 common shares at $7.27. Both transactions occurred on 01/23/2026 and are reported as direct ownership.

At what price were the CorMedix (CRMD) shares in Joseph Todisco’s code F transaction reported?

The code F transaction reported 27,306 shares of CorMedix common stock at a price of $7.27 per share. After this transaction, Todisco’s direct beneficial ownership stood at 697,593 common shares, according to the Form 4 disclosure dated 01/23/2026.

Does Joseph Todisco’s CorMedix (CRMD) equity award involve derivative securities?

The filing describes 225,900 restricted stock units, each representing the right to receive one share of common stock. No separate derivative securities, such as options or warrants, are listed in Table II, focusing the disclosure on time-vested stock unit awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 09:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Todisco Joseph

(Last) (First) (Middle)

C/O CORMEDIX INC.,

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		225,900	A	$0.00(1)	724,899	D
Common Stock	01/23/2026		F		27,306	D	$7.27	697,593	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units granted on 01/23/2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.